AtaiBeckley Inc.
BPL-003 · Mebufotenin Benzoate (5-MeO-DMT) Nasal Spray · Treatment-Resistant Depression
Company Overview
AtaiBeckley Inc. (formed November 2025 from the merger of Atai Life Sciences and Beckley Psytech) is a biopharmaceutical company advancing psychedelic-based therapeutics. On July 16, 2026, Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share in cash (~$2.8 billion), plus contingent value rights of up to $2.50 per share tied to BPL-003 and VLS-01 milestones (~$3.8 billion total) — the first big-pharma acquisition in the psychedelic sector. The deal is expected to close by the end of Q3 2026, subject to shareholder and regulatory approval. Its lead asset BPL-003, a mebufotenin benzoate (5-MeO-DMT) nasal spray, completed Phase 2b with 57.5% remission vs active comparator (p<0.0001) in treatment-resistant depression, and has since begun its two-study Phase 3 program (ReConnection-1 and -2). EMP-01 (oral R-MDMA) reported positive Phase 2a topline data in social anxiety disorder in February 2026, and VLS-01 (DMT buccal film) has a Phase 2b readout expected in Q4 2026.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
BPL-003 Mebufotenin benzoate nasal spray (5-MeO-DMT) | Phase 3 | Treatment-Resistant Depression |
VLS-01 DMT buccal film | Phase 2b | Major Depressive Disorder |
EMP-01 Oral R-MDMA | Phase 2a Complete | Social Anxiety Disorder |
Key Financials
- Cash Position
- $209.9M (runway into 2029)
- Burn Rate
- ~$25-30M/quarter
- Last Reported
- Q1 2026
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- By Q3 2026Eli Lilly acquisition of AtaiBeckley expected to close ($6.75/share cash + up to $2.50 CVR)Corporate
- Q4 2026VLS-01 (DMT buccal film) Phase 2b topline readoutClinical
Recent News
- 2026-07Eli Lilly to acquire AtaiBeckley for $6.75/share cash (~$2.8B, up to ~$3.8B with CVRs); close expected by end of Q3 2026
- 2026-02EMP-01 (oral R-MDMA) reports positive Phase 2a topline in social anxiety disorder
- 2025-12EMP-01 U.S. patent granted December 2025 — exclusivity through 2043
- 2025-12AtaiBeckley redomiciled from Netherlands to Delaware, effective December 30, 2025
- 2025-11Atai Life Sciences and Beckley Psytech merge to form AtaiBeckley Inc.; BPL-003 Phase 2b results lead pipeline
- 2025-07Beckley Psytech BPL-003 Phase 2b: 57.5% remission vs active comparator (0.3mg sub-perceptual dose) in treatment-resistant depression
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 650+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-07-21. Always consult official company filings and a qualified financial advisor before making investment decisions.